Intervention med clarithromycin hos patienter med stabil iskaemisk hjertesygdom: CLARICOR-forsøget-sekundær publikation

CLARICOR-Gruppen

Abstract

Antibiotics may reduce cardiovascular morbidity. We randomised 4372 patients with stable coronary heart disease in the CLARICOR trial to clarithromycin 500 mg (n = 2172) or placebo (n = 2200) daily for a fortnight. After 2.6 years we found significantly increased cardiovascular mortality among the clarithromycin patients. There is a need for studies to evaluate the safety of clarithromycin. There is presently no evidence to support the preventive effect of antibiotics on patients with coronary heart disease.
Bidragets oversatte titelIntervention with clarithromycin in patients with stable coronary heart disease--the CLARICOR trial: secondary publication
OriginalsprogDansk
TidsskriftUgeskrift for Laeger
Vol/bind169
Udgave nummer6
Sider (fra-til)497-9
Antal sider3
ISSN0041-5782
StatusUdgivet - 5 feb. 2007

Fingeraftryk

Dyk ned i forskningsemnerne om 'Intervention med clarithromycin hos patienter med stabil iskaemisk hjertesygdom: CLARICOR-forsøget-sekundær publikation'. Sammen danner de et unikt fingeraftryk.

Citationsformater